Filing Flows › GoodRx Holdings (GDRX) › Q2 2026 › vs Q1 2026
GoodRx Holdings (GDRX) Q2 2026 vs Q1 2026 (quarter over quarter)
GoodRx Holdings's revenue rose $6.4M (+3%) from $194M in Q1 2026 to $200M in Q2 2026. The biggest changes: Pharma Direct revenue +$9.4M (+18%); Prescription transactions revenue −$7.3M (-6%); Subscription revenue +$4.1M (+17%). Operating margin 11.8% against 7.2% (+4.6 pts).
GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%, net earnings $8.5M, operating cash flow $80.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 11.8% | 7.2% | +4.6 pts |
| Net margin | 4.3% | 0.6% | +3.7 pts |
| Free cash flow margin | 40.2% | 5.5% | +34.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Prescription transactions revenue | $106M | $114M | −$7.3M | -6% |
| Pharma Direct revenue | $61.6M | $52.2M | $9.4M | +18% |
| Subscription revenue | $28.5M | $24.4M | $4.1M | +17% |
| Other revenue | $3.9M | $3.7M | $188K | +5% |
| Revenue | $200M | $194M | $6.4M | +3% |
| Operating profit | $23.6M | $14.0M | $9.6M | +69% |
| Costs & expenses | $177M | $180M | −$3.2M | -2% |
| Pre-tax earnings | $15.5M | $5.6M | $9.8M | +174% |
| Other expense, net | $8.2M | $8.4M | −$204K | -2% |
| Cost of revenue | $21.0M | $20.2M | $843K | +4% |
| Research & development | $26.7M | $30.2M | −$3.5M | -11% |
| Sales & marketing | $82.0M | $81.1M | $933K | +1% |
| General & admin | $24.8M | $26.8M | −$2.0M | -7% |
| Other operating costs | $22.3M | $21.8M | $477K | +2% |
| Net earnings | $8.5M | $1.2M | $7.4M | +630% |
| Income tax | $6.9M | $4.5M | $2.5M | +55% |
| Depreciation & amortization | $22.3M | $21.8M | $477K | +2% |
| Share-based compensation | $16.6M | $16.5M | $84K | +0.5% |
| Working capital & other | $33.4M | −$27.6M | $61.1M | — |
| Operating cash flow | $80.8M | $11.8M | $69.0M | +583% |
| Free cash flow (OCF − capex) | $80.5M | $10.7M | $69.8M | +652% |
| Capital expenditures | $362K | $1.1M | −$774K | -68% |
Questions
How much did GoodRx Holdings's revenue grow quarter over quarter in Q2 2026?
GoodRx Holdings's revenue rose $6.4M (+3%) from $194M in Q1 2026 to $200M in Q2 2026.
What drove GoodRx Holdings's revenue change in Q2 2026?
Pharma Direct revenue +$9.4M (+18%); Prescription transactions revenue −$7.3M (-6%); Subscription revenue +$4.1M (+17%).